GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Akums Drugs and Pharmaceuticals Ltd (BOM:544222) » Definitions » EPS (Diluted)

Akums Drugs and Pharmaceuticals (BOM:544222) EPS (Diluted) : ₹6.31 (TTM As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Akums Drugs and Pharmaceuticals EPS (Diluted)?

Akums Drugs and Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Dec. 2024 was ₹4.26. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was ₹6.31.

Akums Drugs and Pharmaceuticals's EPS (Basic) for the three months ended in Dec. 2024 was ₹4.26. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 was ₹6.31.

Akums Drugs and Pharmaceuticals's EPS without NRI for the three months ended in Dec. 2024 was ₹4.03. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2024 was ₹9.78.

During the past 12 months, Akums Drugs and Pharmaceuticals's average EPS without NRIGrowth Rate was 407.50% per year. During the past 3 years, the average EPS without NRIGrowth Rate was 14.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 4 years, Akums Drugs and Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 14.10% per year. The lowest was 14.10% per year. And the median was 14.10% per year.


Akums Drugs and Pharmaceuticals EPS (Diluted) Historical Data

The historical data trend for Akums Drugs and Pharmaceuticals's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akums Drugs and Pharmaceuticals EPS (Diluted) Chart

Akums Drugs and Pharmaceuticals Annual Data
Trend Mar21 Mar22 Mar23 Mar24
EPS (Diluted)
7.80 -15.94 6.22 0.05

Akums Drugs and Pharmaceuticals Quarterly Data
Mar21 Mar22 Mar23 Sep23 Dec23 Mar24 Sep24 Dec24
EPS (Diluted) Get a 7-Day Free Trial 2.02 12.31 -2.32 4.37 4.26

Competitive Comparison of Akums Drugs and Pharmaceuticals's EPS (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Akums Drugs and Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akums Drugs and Pharmaceuticals's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Akums Drugs and Pharmaceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where Akums Drugs and Pharmaceuticals's PE Ratio falls into.


;
;

Akums Drugs and Pharmaceuticals EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Akums Drugs and Pharmaceuticals's Diluted EPS for the fiscal year that ended in Mar. 2024 is calculated as

Diluted EPS (A: Mar. 2024 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(7.9-0)/157.394
=0.05

Akums Drugs and Pharmaceuticals's Diluted EPS for the quarter that ended in Dec. 2024 is calculated as

Diluted EPS (Q: Dec. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(651.82-0)/153.009
=4.26

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹6.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Akums Drugs and Pharmaceuticals  (BOM:544222) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Akums Drugs and Pharmaceuticals EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Akums Drugs and Pharmaceuticals's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Akums Drugs and Pharmaceuticals Business Description

Traded in Other Exchanges
Address
Akums House, Plot No. 131 to 133, Block C, Mangolpuri Industrial Area Phase1, Adjoining CBSE Office, Delhi, IND, 110083
Akums Drugs and Pharmaceuticals Ltd a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. Its services include formulation research and development (R&D), preparation and filing of regulatory dossiers in the Indian and Outside markets, and other testing services. It is also engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (APIs). The operates in three segments: a) Contract Development and Manufacturing Operations (CDMO), b) Active Pharmaceutical Ingredient (API), and c) Branded and Generic formulations. Key revenue is generated from Contract Development and Manufacturing Operations (CDMO).

Akums Drugs and Pharmaceuticals Headlines

No Headlines